AvenCell Therapeutics Begins Phase I Study for Dual-Targeting CAR-T Therapy in B-Cell Cancer
AvenCell Therapeutics, Inc., a prominent player in the field of cell therapy, recently announced a major milestone. The company has successfully dosed the first patient in its Phase I QUADvance study (AVC-203-01; NCT07284433) with its investigational CAR-T therapy, AVC-203. This innovative treatment specifically aims at relapsed and refractory B-cell malignancies, providing hope to a patient demographic that often has limited treatment options
AVC-203 represents a groundbreaking advancement in CAR-T therapy, being the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable therapy undergoing clinical testing. This therapeutic candidate uniquely employs a dual-targeting strategy directed at both CD19 and CD20 receptors, which are prevalent in various B-cell malignancies, including the aggressive diffuse large B-cell lymphoma (DLBCL). The therapy uses cutting-edge CRISPR technology for its engineering, aiming to provide a more effective treatment option for patients in dire need.
One of the standout features of AVC-203 is its combination of a proprietary dimerized receptor (RevCAR) with the dual-targeting mechanism. This approach enables flexibility in future applications, allowing expansion of targets beyond CD19 and CD20 through bi- or tri-specific bridging proteins, enhancing its potential utility in treating complex cases.
Dr. Martin Wermke, leading the Early Clinical Trial Unit at the National Cancer Center in Dresden, Germany, emphasized the need for such innovative strategies, stating that patients suffering from relapsed/refractory B-cell malignancies often find themselves devoid of effective treatment alternatives and face poor prognoses. AvenCell's novel approach, by enabling more versatile targeting options, holds promise for improving treatment outcomes in this challenging area of oncology.
Andrew Schiermeier, AvenCell's CEO and President, expressed excitement about this development, framing it as a significant achievement within the domain of allogeneic cell therapy. He highlighted the company’s commitment to ensuring that patients in need can easily access CAR-T therapies, citing advancements in manufacturing that aim to drastically reduce costs and increase availability. This commitment is crucial as it addresses current hurdles that limit the reach of existing CAR-T therapies.
Supporting this ambitious project, AvenCell has secured substantial backing in the form of a $40 million grant from the Japan Agency for Medical Research and Development (AMED). This funding will aid in the further clinical development of AVC-203 in Japan, concurrent with the company’s goal to deliver this groundbreaking therapy across the Asia-Pacific region. The swift advancement of this program reflects AvenCell's global vision to enhance treatment accessibility and efficacy in B-cell malignancies.
Notably, AvenCell achieved both FDA IND clearance and EMA approval for its Clinical Trial Application for the QUADvance study in late 2025, allowing multi-site trials to commence in the US and Europe. This regulatory success underlines the technology's promising potential within oncological research, particularly in relation to the needs of patients whose conditions have not sufficiently improved with existing therapies.
AVC-203 emphasizes four primary innovations: dual antigen targeting through a proprietary receptor, immune evasion to minimize rejection risks, improved T-cell fitness for off-the-shelf availability, and switchable targeting technology. These features not only optimize the therapeutic effectiveness but also facilitate immediate access to treatment for patients with acute needs. The ongoing QUADvance study evaluates the safety, tolerability, and efficacy of AVC-203 in adults with relapsed or refractory B-cell malignancies, aiming for a comprehensive understanding of its pharmacokinetics.
B-cell malignancies, which encompass non-Hodgkin lymphomas, multiple myeloma, and B-cell acute lymphoblastic leukemia, represent a significant segment of blood cancers, with hundreds of thousands of new cases diagnosed annually in both the US and Europe. With existing autologous CAR-T therapies facing challenges like prolonged manufacturing time, high costs, and restricted accessibility, AvenCell's allogeneic CAR-T therapy could serve as a vital alternative.
AvenCell was established with a vision to transform cell therapy for tough-to-treat cancers. Its research and operational facilities are headquartered in Watertown, Massachusetts, with key clinical and manufacturing operations also based in Dresden, Germany. The company aims to redefine the landscape of cell therapy by developing allogeneic solutions that can potentially match or exceed the performance of traditional autologous therapies.
In summary, the initiation of the QUADvance study offers a beacon of hope for patients suffering from challenging B-cell malignancies. As the field of CAR-T therapy continues to evolve, AvenCell Therapeutics is at the forefront, endeavoring to pioneer innovative therapies that promise to change the future of cancer treatment for many patients around the world.
AVC-203 represents a groundbreaking advancement in CAR-T therapy, being the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable therapy undergoing clinical testing. This therapeutic candidate uniquely employs a dual-targeting strategy directed at both CD19 and CD20 receptors, which are prevalent in various B-cell malignancies, including the aggressive diffuse large B-cell lymphoma (DLBCL). The therapy uses cutting-edge CRISPR technology for its engineering, aiming to provide a more effective treatment option for patients in dire need.
One of the standout features of AVC-203 is its combination of a proprietary dimerized receptor (RevCAR) with the dual-targeting mechanism. This approach enables flexibility in future applications, allowing expansion of targets beyond CD19 and CD20 through bi- or tri-specific bridging proteins, enhancing its potential utility in treating complex cases.
Dr. Martin Wermke, leading the Early Clinical Trial Unit at the National Cancer Center in Dresden, Germany, emphasized the need for such innovative strategies, stating that patients suffering from relapsed/refractory B-cell malignancies often find themselves devoid of effective treatment alternatives and face poor prognoses. AvenCell's novel approach, by enabling more versatile targeting options, holds promise for improving treatment outcomes in this challenging area of oncology.
Andrew Schiermeier, AvenCell's CEO and President, expressed excitement about this development, framing it as a significant achievement within the domain of allogeneic cell therapy. He highlighted the company’s commitment to ensuring that patients in need can easily access CAR-T therapies, citing advancements in manufacturing that aim to drastically reduce costs and increase availability. This commitment is crucial as it addresses current hurdles that limit the reach of existing CAR-T therapies.
Supporting this ambitious project, AvenCell has secured substantial backing in the form of a $40 million grant from the Japan Agency for Medical Research and Development (AMED). This funding will aid in the further clinical development of AVC-203 in Japan, concurrent with the company’s goal to deliver this groundbreaking therapy across the Asia-Pacific region. The swift advancement of this program reflects AvenCell's global vision to enhance treatment accessibility and efficacy in B-cell malignancies.
Notably, AvenCell achieved both FDA IND clearance and EMA approval for its Clinical Trial Application for the QUADvance study in late 2025, allowing multi-site trials to commence in the US and Europe. This regulatory success underlines the technology's promising potential within oncological research, particularly in relation to the needs of patients whose conditions have not sufficiently improved with existing therapies.
AVC-203 emphasizes four primary innovations: dual antigen targeting through a proprietary receptor, immune evasion to minimize rejection risks, improved T-cell fitness for off-the-shelf availability, and switchable targeting technology. These features not only optimize the therapeutic effectiveness but also facilitate immediate access to treatment for patients with acute needs. The ongoing QUADvance study evaluates the safety, tolerability, and efficacy of AVC-203 in adults with relapsed or refractory B-cell malignancies, aiming for a comprehensive understanding of its pharmacokinetics.
B-cell malignancies, which encompass non-Hodgkin lymphomas, multiple myeloma, and B-cell acute lymphoblastic leukemia, represent a significant segment of blood cancers, with hundreds of thousands of new cases diagnosed annually in both the US and Europe. With existing autologous CAR-T therapies facing challenges like prolonged manufacturing time, high costs, and restricted accessibility, AvenCell's allogeneic CAR-T therapy could serve as a vital alternative.
AvenCell was established with a vision to transform cell therapy for tough-to-treat cancers. Its research and operational facilities are headquartered in Watertown, Massachusetts, with key clinical and manufacturing operations also based in Dresden, Germany. The company aims to redefine the landscape of cell therapy by developing allogeneic solutions that can potentially match or exceed the performance of traditional autologous therapies.
In summary, the initiation of the QUADvance study offers a beacon of hope for patients suffering from challenging B-cell malignancies. As the field of CAR-T therapy continues to evolve, AvenCell Therapeutics is at the forefront, endeavoring to pioneer innovative therapies that promise to change the future of cancer treatment for many patients around the world.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.